173 CpG Sites - the markers behind your clock

173 CpG sites sound like a technical footnote. In practice, they point to one of the most important shifts in longevity measurement: away from a single biological age estimate and toward a signal for pace.

DunedinPACE does not simply ask how biologically old a body is. It tries to estimate how quickly physiological systems are changing over time. That is why the marker matters for ARES: not as a verdict, but as another context layer in a broader navigation system.

Context

DNA methylation is a chemical mark on DNA. At specific CpG sites, methylation patterns can vary with age, environment, cell composition and biological stress. The first major generation of epigenetic clocks became widely known through Horvath's work, DNA methylation age of human tissues and cell types (https://pubmed.ncbi.nlm.nih.gov/24138928/). That work showed that methylation patterns can carry surprisingly strong age-related information.

The important distinction is this: a clock is not an organ, symptom or diagnosis. It is a statistical model. It combines many methylation sites into a score. The score can be useful, but it remains a proxy.

DunedinPACE uses a different frame. The eLife paper by Belsky et al. 2022 (https://pubmed.ncbi.nlm.nih.gov/35029144/) describes a blood-test biomarker for the pace of biological aging. The name points back to the Dunedin Study, a longitudinal cohort in which many body-system changes were observed over time.

Why 173 CpG sites matter

The number 173 is not a secret biological code. It represents a reduced set of methylation sites derived from a much larger measurement space. The model uses those sites to reconstruct a pace signal.

That matters for product design. A system like ARES must not claim more than the signal can support. One DunedinPACE value does not prove whether an intervention worked. It does not classify a user as healthy or sick. It can, however, act as a state variable:

• does the pace signal move across repeated measurements?
• does it move with sleep, HRV, inflammation markers or blood lipids?
• does it contradict the rest of the picture and therefore require more context?
• are the measurements comparable, or did lab, platform or sample handling change?

The value is not the score as truth. The value is signal fusion.

Evidence frame

The earlier DunedinPoAm (https://pubmed.ncbi.nlm.nih.gov/32367804/) work already focused on quantifying biological aging pace. GrimAge, described by Lu et al. (https://pubmed.ncbi.nlm.nih.gov/30669119/), showed that methylation models can be associated with lifespan- and healthspan-related endpoints.

These papers make epigenetic clocks important. They do not turn them into automatic decision systems. Most models remain dependent on cohort, lab method, population, cell-type composition and calibration. A score can also move because of inflammation, technical platform changes or sample context.

For a serious content and product pipeline, the interpretation must stay bounded:

| Question | Bounded interpretation | |---|---| | What does the clock measure? | A modeled methylation signal, not aging itself | | What can one value provide? | Context, hypothesis, one longitudinal point | | What does quality require? | Repeated measurement, metadata and comparison with other signals | | What creates risk? | Overclaiming, score obsession, direct action from a single value |

ARES perspective

ARES treats an epigenetic clock as one layer inside the Bio-Velocity model. The clock does not describe the person. It describes one signal about the person.

Practically, that value belongs next to sleep architecture, HRV, training load, inflammation markers, lipids, glucose dynamics and subjective state. The relationship between those layers is the useful object.

For example, a faster pace signal together with poor sleep architecture, high training load and elevated inflammation markers has a different meaning than an isolated outlier in an otherwise stable period. In the other direction, a better score without context is not proof of efficacy.

Risks

The biggest risk is not the measurement itself. It is the story built around the measurement. Epigenetic scores sound objective, which makes them attractive for marketing and dangerous for users.

Common misreadings include:

• treating a single score as a diagnosis
• overinterpreting small changes
• mixing different clock generations as if they were interchangeable
• ignoring lab or platform changes
• selling a proxy as proof that an intervention worked

A serious product logic has to prevent these errors. Every article, worker and pipeline that touches clocks needs a claim-safety check.

Key takeaways

• DunedinPACE is interesting because it models pace rather than only state.
• The 173 CpG sites are a reduced signal set, not a biological secret code.
• The value becomes useful in sequence and in comparison with other signals.
• For ARES, the clock is a Bio-Velocity context signal, not a medical verdict.

Disclaimer

This document is for education and scientific context only. It is not diagnosis, treatment advice or self-medication guidance. Epigenetic testing needs qualified clinical context whenever health decisions depend on it.

Sources

• Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022. DOI: 10.7554/eLife.73420. PMID: 35029144.
• Belsky DW et al. Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. eLife. 2020. DOI: 10.7554/eLife.54870. PMID: 32367804.
• Horvath S. DNA methylation age of human tissues and cell types. Genome Biology. 2013. DOI: 10.1186/gb-2013-14-10-r115. PMID: 24138928.
• Lu AT et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019. DOI: 10.18632/aging.101684. PMID: 30669119.

<!-- tags: Epigenetics, DunedinPACE, Methylation, Bio-Velocity -->